SIGA - NASDAQ

SIGA Technologies, Inc.

SIGA·NASDAQ

$4.32

-0.69%

HealthcareDrug Manufacturers - Specialty & Generic

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$309.85M

EPS0.3300

P/E Ratio18.78

Earnings Date07/30/2026

siga

Net Debt

Last Annual Value

-154.37M

3-Year CAGR

-16%

5-Year CAGR

-6%

10-Year CAGR

-3%

Adjust for Inflation

SIGA Technologies, Inc. Competitors Analysis of Net Debt

SIGA · NASDAQ

Company	Net Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
SIGA Technologies, Inc. NASDAQ:SIGA	-154.37M	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL	12.72M	-22.9%	1.7%	N/A
Aquestive Therapeutics, Inc. NASDAQ:AQST	10.28M	2.8%	-18.4%	-10.0%
Ventyx Biosciences, Inc. NASDAQ:VTYX	-16.47M	N/A	N/A	N/A
Esperion Therapeutics, Inc. NASDAQ:ESPR	380.15M	-6.1%	49.3%	N/A
DarioHealth Corp. NASDAQ:DRIO	5.50M	N/A	N/A	N/A
Emergent BioSolutions Inc. NYSE:EBS	366.70M	-21.2%	4.5%	N/A
CytomX Therapeutics, Inc. NASDAQ:CTMX	-8.43M	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. NASDAQ:OLMA	-47.11M	N/A	N/A	N/A
Organogenesis Holdings Inc. NASDAQ:ORGO	39.16M	37.7%	16.3%	N/A

SIGA Technologies, Inc. Fair Value Envelope

SIGA · NASDAQ

Our analysis suggests that SIGA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.32, this represents a potential HIDDEN relative to our calculated worth for SIGA Technologies, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.32

Related Guides

Blog Categories

Continue your SIGA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.